Company profile for Beijing Avistone Pharmaceuticals Biotechnology

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Avistone is a dedicated oncology company with a focus on developing innovative therapies to address the significant unmet medical needs of patients globally. The company boasts an extensive pipeline that includes two clinical-stage drug candidates and several ongoing programs in the pre-clinical development stage. Avistone's lead asset, PLB1001, is a small-molecule inhibitor targeting MET tyrosine kinase activity, particularly...
Avistone is a dedicated oncology company with a focus on developing innovative therapies to address the significant unmet medical needs of patients globally. The company boasts an extensive pipeline that includes two clinical-stage drug candidates and several ongoing programs in the pre-clinical development stage. Avistone's lead asset, PLB1001, is a small-molecule inhibitor targeting MET tyrosine kinase activity, particularly addressing aberrant activity associated with METexon14 skipping genetic alterations in NSCLC tumors and other solid tumors.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
Lize Middle 2nd Road, Chaoyang District, Beijing
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20250531731865/en/Avistone-Announces-Encouraging-Results-for-Vebreltinib-plus-Andamertinib-PLB1004-in-EGFR-mutated-NSCLC-with-MET-Amplification-or-Overexpression-at-ASCO-Annual-Meeting-2025

BUSINESSWIRE
31 May 2025

https://www.businesswire.com/news/home/20250415613561/en/Avistone-Announces-Preclinical-Results-for-ANS03-a-Novel-Type-II-ROS1NTRK-Inhibitor-in-Overcoming-Clinically-Relevant-ROS1NTRK-Resistance-Mutations-at-AACR-Annual-Meeting-2025

BUSINESSWIRE
15 Apr 2025
Avistone Announces Updates on ANS03
Avistone Announces Updates on ANS03

04 Dec 2024

// BUSINESSWIRE

https://www.businesswire.com/news/home/20241204521875/en

BUSINESSWIRE
04 Dec 2024
Avistone Announces Updates on ANS014004
Avistone Announces Updates on ANS014004

04 Oct 2024

// BUSINESSWIRE

https://www.businesswire.com/news/home/20241004946427/en

BUSINESSWIRE
04 Oct 2024

https://www.businesswire.com/news/home/20240910500605/en

BUSINESSWIRE
10 Sep 2024

https://www.businesswire.com/news/home/20240604496164/en

BUSINESSWIRE
04 Jun 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty